Neumora Therapeutics (NMRA) EBIT (2022 - 2026)
Neumora Therapeutics (NMRA) recorded quarterly EBIT of -$52.9 million in Q1 2026, up 9.6% quarter-over-quarter from -$58.5 million in Q4 2025, and up 25.48% on a YoY basis from -$42.1 million in Q1 2025.
Neumora Therapeutics (NMRA) EBIT (2022 - 2026) Analysis & Trends
Neumora Therapeutics' EBIT history runs 5 years deep, the most recent figure standing at -$52.9 million for Q1 2026.
- In Q1 2026, EBIT rose 25.48% year-over-year to -$52.9 million; the TTM figure through Mar 2026 stood at -$223.1 million (up 18.68% YoY), while the FY2025 annual figure was -$241.2 million, up 8.47% from the prior year.
- EBIT was -$52.9 million for Q1 2026 at Neumora Therapeutics, up from -$58.5 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$30.6 million in Q3 2022 to a low of -$114.0 million in Q4 2023.
- Historically, EBIT has averaged -$58.1 million across 5 years, with a median of -$57.7 million in 2025.
- The sharpest annual moves came in 2023 and 2024: EBIT sank 271.13% in 2023, then soared 44.81% in 2024.
- A 5-year view of EBIT shows it stood at -$30.7 million in 2022, then tumbled by 271.13% to -$114.0 million in 2023, then jumped by 44.81% to -$62.9 million in 2024, then climbed by 7.06% to -$58.5 million in 2025, then rose by 9.6% to -$52.9 million in 2026.
- The last three EBIT figures came in at -$52.9 million (Q1 2026), -$58.5 million (Q4 2025), and -$57.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Neumora Therapeutics | 270.71 Mn | 270.71 Mn | - | -52.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.86 Mn |
| Dec 31, 2025 | -58.48 Mn |
| Sep 30, 2025 | -57.70 Mn |
| Jun 30, 2025 | -54.04 Mn |
| Mar 31, 2025 | -70.94 Mn |
| Dec 31, 2024 | -62.92 Mn |
| Sep 30, 2024 | -76.65 Mn |
| Jun 30, 2024 | -63.82 Mn |
| Mar 31, 2024 | -60.07 Mn |
| Dec 31, 2023 | -114.00 Mn |
| Sep 30, 2023 | -56.86 Mn |
| Jun 30, 2023 | -42.06 Mn |
| Mar 31, 2023 | -39.17 Mn |
| Dec 31, 2022 | -30.72 Mn |
| Sep 30, 2022 | -30.60 Mn |